Cargando…
mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure
BACKGROUND: Depression is a prevalent neuropsychiatric disorder that affects an estimated 350 million people worldwide. Currently available treatments for depression are lacking in both speed of onset and efficacy. Recent pharmacological efforts have targeted the glutamatergic neurotransmitter syste...
Autores principales: | Dwyer, Jason M, Lepack, Ashley E, Duman, Ronald S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224009/ https://www.ncbi.nlm.nih.gov/pubmed/25408908 http://dx.doi.org/10.1186/2049-9256-1-15 |
Ejemplares similares
-
Group I mGluRs in Therapy and Diagnosis of Parkinson’s Disease: Focus on mGluR5 Subtype
por: Azam, Shofiul, et al.
Publicado: (2022) -
Extinction-Dependent Alterations in Corticostriatal mGluR2/3 and mGluR7 Receptors following Chronic Methamphetamine Self-Administration in Rats
por: Schwendt, Marek, et al.
Publicado: (2012) -
Metabotropic glutamate receptors (mGluRs) in epileptogenesis: an update on abnormal mGluRs signaling and its therapeutic implications
por: Huang, Leyi, et al.
Publicado: (2023) -
BDNF Release Is Required for the Behavioral Actions of Ketamine
por: Lepack, Ashley E., et al.
Publicado: (2014) -
mGluR5, CB1 and neuroprotection
por: Carvalho, Toniana G., et al.
Publicado: (2016)